検索結果

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

announce today that it has been applied for manufacturing and marketing approval in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

ound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs when central retinal artery occlusion leads to irreversible impairment of...